Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Product Development Meetings With FDA To Be Flexible Under User Fee Program

Sep 15 2011

• By The Pink Sheet Daily

Related Content

ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five

Sep 12 2011

Biosimilar User Fees Would Be Same As BLAs, Only Earlier

May 09 2011

Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees

Aug 22 2011

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window